Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
August 2, 2022 4:06 PM EDT-Â Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million
-Â Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year
-Â Â Increased full-year total revenue and net product revenue guidance to a range of $905-$920 million and $825-$840 million, respectivelyÂ
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the... More
